The US company's first-quarter revenues surged 77% to over $25bn compared to the same period last year, driven by $13.2bn in Covid vaccine sales. However, Pfizer has downgraded its profit guidance for the year amid rising research and development costs.
Pfizer cuts 2022 earnings outlook even as Q1 sales rise
Share
